List view / Grid view

Dr Judith M. Sills (Arriello)

 

article

Navigating pharmacovigilance complexity in the US and EU: notes for biotechs

15 June 2021 | By ,

Pharmacovigilance obligations present significant challenges for biotechs. Small companies face the same rigor as large pharma - and it does not help that there is divergence between the requirements of the FDA, the EU and its member states. Here, seasoned pharmacovigilance experts and non-executive advisors to Arriello, Eric Caugant in…